قال تعالى:

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ
أَرَايَ أَنَّكَ أَلَّذِي خَلَقْتُ ۖ خَلَقَ الْإِنْسَانَ مِنْ عَلَىٰ أَفْرَاشِكَ
الْأَكْرَمِ ۗ أَلَّذِي عَلَىٰ الْقُلُوبِ عَلَىٰ الْإِنْسَانِ مَالِ الرَّيْطَمِ

فيما يُعَلِّقُ

الآيات 1-5

صدق الله العظيم
Acknowledgements

Thanks are first and last to Allah who enabled me to conduct this study by the grace of him and denoted strength and patience.

I am grateful to my supervisor Dr. Mohammed Abd El-Rahim. For his skilful guidance, wisdom, enthusiastic and encouragements through the progress of this research.

We are indebted to our family members for their patience, encouragement and moral support during this research.

Sincere gratitude extending to our friends, colleagues and relatives who assisted me in one way or another.
إهداء
أهدي ثمرة هذا الجهد المتواضع إلى أعز الناس إلى أمي نبع الحنان الدافق إلى أبي رمز البذل والعطاء إلى إخوتي وزملائي وزميلاتي
إلى أساتذتي الأجلاء وكل من أسهم معي في مشوار حياتي
ABSTRACT

This study conducted during the period March to September 2010, compared serum levels of Alanine transaminase, To study the effect of diabetes mellitus on the serum activity of ALT, of 60 diabetic patients, chosen from diabetic center, Khartoum North. And hag Elssafi hospital, (in Khartoum state) and 20 apparently, health individuals as controls.

Patients with diabetes mellitus had significantly higher serum ALT levels, as measured by spectrophotometric method. The main serum ALT was 25.7(SD 7.9)u/l, in the diabetic group, compared to 17.9 (SD5.7)u/l in the control group (p<0.05).but the increased ALT were within the normal reference value.

To study the effect of the duration of diabetes mellitus on serum levels of the liver enzyme. Alanine transaminase (ALT), the diabetic group of patient (n=60) was divided
into two subgroups; <10 years duration of the disease (n=27) and > 10 years duration (n=33). It was found that, serum ALT, they show significant increase with increase duration of the disease. But still any alteration of activity were within the normal value

The following result was obtained. The mean serum ALT levels (<10 years: 22.5±8.1 u/l and > 10 years: 28.3±6.8 u/l p<0.05).

To study the effect of age with diabetes mellitus on serum levels of Alanine transaminase (ALT), the diabetic group of patient (n=60) was divided into two subgroups; <40 years (n=9) and > 40 years duration (n=51). It was found that, serum ALT, although they were significantly raised in the diabetes group (n=60), they don't show any significant increase with increase of age.
The following result was obtained. The mean serum ALT levels (<40 years: 24.9±9.4 u/l and > 40 years: 25.8±7.7 u/l p>0.05)

To study the effect of sex with diabetes mellitus on serum levels of Alanine transaminase (ALT), the diabetic group of patient (n=60) was divided into two subgroups; male (n=39) and female (n=21). It was found that, serum ALT, although they were significantly raised in the diabetes group (n=60), they don't show any significant increase with sex.

The following result was obtained. The mean serum ALT levels (male: 27.1±7.6 u/l and female: 23.1±8.1 u/l p>0.05)
الملخص

أجريت هذه الدراسة خلال الفترة من مارس وحتى سبتمبر عام 2010، بمقارنة لدراسة مدى تأثير مرض السكري على مستويات إنزيم الalanine transaminase (ALT) نشاط الإنزيم (ALT) في مجموعة مقارنة. وكان نشاط إنزيم الalanine transaminase عند المرضى الذين يعانون من مرض السكري أعلى من مستوياته عند الأصحاء، إذما قيس جهاز الاستكرور فحص وتحديده بلغ 25.7 وحدها لتر بانحراف معياري (7.9). وقيمه ذات دلالة لا تعدي (ALT) لكن هذه الزيادة في إنزيم (ALT) لا تعدي (p.value<(0.05)


تم الحصول على النتيجة التالية (ALT) (p.value<0.05).

ومجموعة من مرضى السكري (n = 60) إلى مجموعتين فرعتين: أقل من 40 سنة (n = 40) وأكبر (n = 20) على الرغم من أنه تأثر بشكل كبير في (ALT). وقد تبين أن المجموعة السكرية (n = 60) التي لا تظهر أي زيادة كبيرة مع زيادة العمر.

تم الحصول على النتيجة التالية (ALT) (p.value<0.05).

ومجموعة من مرضى السكري (n = 60) إلى مجموعتين فرعتين: الذكور (n = 39) وإناث (n = 21). تم العثور على أن مرضى السكري (n = 60) لا تظهر أي زيادة كبيرة مع الجنس.

التالي: (ALT) (p.value<0.05).

الذكور: 27.1 ± 8.1 وحدها لتر و (ALT) (p.value>0.05).
# Contents

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>II</td>
<td>II</td>
</tr>
<tr>
<td>III</td>
<td>III</td>
</tr>
<tr>
<td>IV</td>
<td>IV</td>
</tr>
<tr>
<td>Abstract</td>
<td>9</td>
</tr>
<tr>
<td>List of content</td>
<td>9</td>
</tr>
<tr>
<td>list of table</td>
<td>X</td>
</tr>
<tr>
<td><strong>Chapter One</strong></td>
<td></td>
</tr>
<tr>
<td>1.1. Introduction</td>
<td>1</td>
</tr>
<tr>
<td>1.2. Literature review</td>
<td>5</td>
</tr>
<tr>
<td>1.2.1. Diabetes mellitus</td>
<td>5</td>
</tr>
<tr>
<td>1.2.1.1. Definition of diabetes mellitus</td>
<td>5</td>
</tr>
<tr>
<td>1.2.1.2. Types of diabetes mellitus</td>
<td>5</td>
</tr>
<tr>
<td>1.2.1.2.1. Type 1 diabetes mellitus</td>
<td>5</td>
</tr>
<tr>
<td>1.2.1.2.2. Type 2 diabetes mellitus</td>
<td>6</td>
</tr>
<tr>
<td>1.2.1.2.3. Insulin resistance</td>
<td>6</td>
</tr>
<tr>
<td>1.2.1.2.4. Loss of β-cell Function</td>
<td>7</td>
</tr>
<tr>
<td>1.2.1.3. Type 2 diabetes mellitus</td>
<td>8</td>
</tr>
<tr>
<td>1.2.1.3.1. Signs, symptoms and causes</td>
<td>8</td>
</tr>
<tr>
<td>1.2.1.3.2. Medical conditions</td>
<td>9</td>
</tr>
<tr>
<td>1.2.1.3.3. Pathophysiology</td>
<td>10</td>
</tr>
</tbody>
</table>
1.2.1.4. Anti diabetic drugs

1.2.1.5. Complication of diabetes

1.2.1.6. Insulin as treatment

1.2.1.7.1. History of Insulin

1.2.2. Enzymes

1.2.2.1. Basic principles

1.2.2.2. Enzymes nomenclature

1.2.2.3. Enzymes as proteins Basic structure

1.2.2.4. Isoenzymes and other multiple forms of enzymes

1.2.2.5. Liver enzymes

1.2.2.5.1. Aminotransferases

1.3. Objective

1.3.1. General objective

1.3.2. Specific objective

Chapter Two

2. Material and methods

2.1. Materials

2.1.1. Subjects

2.1.2. Samples

2.2. Methods

2.2.1. Estimate of blood glucose

2.2.1.1. Principle

2.2.1.2. Sample

2.2.1.3. Reagent
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.2.1.4.Procedure</td>
<td>34</td>
</tr>
<tr>
<td>2.2.1.5.Calculation</td>
<td>35</td>
</tr>
<tr>
<td>2.2.1.6.Reference Value</td>
<td>35</td>
</tr>
<tr>
<td>2.2.2.Estimate of ALT activity</td>
<td>35</td>
</tr>
<tr>
<td>2.2.2.1.Principle</td>
<td>35</td>
</tr>
<tr>
<td>2.2.2.2.Reagents</td>
<td>35</td>
</tr>
<tr>
<td>2.2.2.3.Additional Equipment</td>
<td>35</td>
</tr>
<tr>
<td>2.2.2.4.Procedure</td>
<td>36</td>
</tr>
<tr>
<td>2.2.2.5.Calculation</td>
<td>36</td>
</tr>
<tr>
<td>2.2.2.6.Reference Value</td>
<td>36</td>
</tr>
<tr>
<td>2.3.Statistical analysis</td>
<td>36</td>
</tr>
</tbody>
</table>

**Chapter three**

3. The result                                                        | 37   |

**Chapter four**

4.1.Discussion                                                      | 43   |
4.2.Conclusion                                                      | 46   |
4.3.recommendation                                                  | 47   |
**References**                                                      | 48   |
**Appendix**                                                        | 52   |
List of tables

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>(3.1)</td>
<td>the Frequency and Percent of duration</td>
<td>39</td>
</tr>
<tr>
<td>(3.2)</td>
<td>sex distribution in diabetic patients</td>
<td>39</td>
</tr>
<tr>
<td>(3.3)</td>
<td>the age grouping</td>
<td>40</td>
</tr>
<tr>
<td>(3.4)</td>
<td>the Mean and P. value (t. test) of RBS and ALT activity in 2 study groups.</td>
<td>40</td>
</tr>
<tr>
<td>(3.5)</td>
<td>the Mean and Std. Deviation and P. value (t. test) of ALT according to age</td>
<td>41</td>
</tr>
<tr>
<td>(3.6)</td>
<td>the Mean and Std. Deviation and P. value (t. test) of ALT activity in diabetic patients according to gender</td>
<td>41</td>
</tr>
<tr>
<td>(3.7)</td>
<td>the Mean and Std. Deviation and P. value (t. test) of ALT according to Duration</td>
<td>42</td>
</tr>
</tbody>
</table>